Latest Period
Q1 2026
Security Snapshot
Karyopharm Therapeutics Inc. - COMMON STOCK (KPTI) Institutional Ownership
CUSIP: 48576U205
13F Institutional Holders and Ownership History from Q1 2025 to Q2 2026
Institutions Reporting
76
Shares (Excl. Options)
17,581,515
Price
$5.57
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- KPTI on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 17,581,515
- Total 13F value
- $97,927,900
- Portfolio coverage rank
- 0%
- Share change
- +7,822,113
- Value change
- +$39,559,074
- Number of holders
- 76
- Shares outstanding
- 23,320,409
- SEC-reported price per share
- $9.88
- Insider filing price
- $9.88
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- KPTI - Karyopharm Therapeutics Inc. - COMMON STOCK is tracked under CUSIP 48576U205.
- 76 institutions reported positions in Q1 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 76 to 2 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $97,927,900 to $101,394.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 76 institutions filings for Q1 2026.
Security key
48576U205
Latest holder period
Q1 2026
13F holders
76
13D/G owners
9
CIK / CUSIP context first
Open Q1 2026 holders
KPTI full holder history
Karyopharm Therapeutics Inc. SEC filings
Karyopharm Therapeutics Inc. company facts
Karyopharm Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 48576U205:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
KPTI
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 8.6% | +9.6% | $12,870,974 | +$7,880,460 | 1,713,092 | +158% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| Opaleye Management Inc. | 9.5% | $10,262,842 | 1,569,002 | Opaleye Management Inc. | 10 Oct 2025 | |||
| T. Rowe Price Investment Management, Inc. | 6.6% | -43% | $13,729,191 | -$6,291,044 | 1,539,147 | -31% | T. Rowe Price Investment Management, Inc. | 31 May 2026 |
| INTEGRATED CORE STRATEGIES (US) LLC | 5.5% | $7,252,280 | 1,008,662 | Millennium Management LLC | 04 Feb 2026 | |||
| J. WOOD CAPITAL ADVISORS LLC | 5% | $6,546,231 | 1,000,708 | J. Wood Capital Advisors LLC | 14 Oct 2025 | |||
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 4.9% | $4,250,895 | 649,984 | HIGHBRIDGE CAPITAL MANAGEMENT, LLC | 30 Sep 2025 | |||
| Adage Capital Management, L.P. | 2.4% | $3,140,132 | 436,736 | Adage Capital Management, L.P. | 31 Dec 2025 | |||
| JPMORGAN CHASE & CO | 4.9% | -6% | $2,797,089 | -$149,213 | 427,624 | -5.1% | JPMORGAN CHASE & CO. | 30 Sep 2025 |
| VANGUARD GROUP INC | 4.7% | $2,670,221 | 408,222 | The Vanguard Group | 30 Sep 2025 |
As of 31 Mar 2026, 76 institutional investors reported holding 17,581,515 shares of Karyopharm Therapeutics Inc. - COMMON STOCK (KPTI). This represents 75% of the company’s total 23,320,409 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
67%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Commodore Capital LP | 8.4% | 1,950,000 | 0.63% | $10,861,500 | |
| RA CAPITAL MANAGEMENT, L.P. | 8.2% | 1,917,354 | 0.11% | $10,679,662 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.7% | 1,806,322 | +329% | 0.02% | $10,061,214 |
| T. Rowe Price Investment Management, Inc. | 6.6% | 1,542,090 | +3.4% | 0.01% | $8,590,000 |
| GOLDMAN SACHS GROUP INC | 4.1% | 947,579 | 0% | $5,278,015 | |
| Catalio Capital Management, LP | 3.8% | 897,709 | +528% | 1% | $5,000,239 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 739,745 | 0% | 0% | $4,120,380 |
| Ikarian Capital, LLC | 3.1% | 733,435 | +35% | 0.59% | $4,085,233 |
| Affinity Asset Advisors, LLC | 2.1% | 500,000 | -44% | 0.16% | $2,785,000 |
| Avidity Partners Management LP | 2% | 463,741 | +245% | 0.51% | $2,583,037 |
| Soleus Capital Management, L.P. | 1.9% | 440,000 | 0% | 0.1% | $2,450,800 |
| MILLENNIUM MANAGEMENT LLC | 1.8% | 420,571 | 0% | $2,342,580 | |
| Boxer Capital Management, LLC | 1.3% | 302,536 | +20% | 0.22% | $1,685,126 |
| Davidson Kempner Capital Management LP | 1.3% | 300,000 | -3.2% | 0.04% | $1,671,000 |
| ACORN CAPITAL ADVISORS, LLC | 1.2% | 287,826 | 0.46% | $1,603,191 | |
| Eversept Partners, LP | 1.2% | 276,174 | 0.1% | $1,538,289 | |
| Jump Financial, LLC | 1.1% | 262,146 | +387% | 0.02% | $1,460,153 |
| Trexquant Investment LP | 1.1% | 257,903 | +518% | 0.01% | $1,436,520 |
| ACADIAN ASSET MANAGEMENT LLC | 1.1% | 248,957 | +6582% | 0% | $1,382,000 |
| BlackRock, Inc. | 1.1% | 244,899 | -1.1% | 0% | $1,364,087 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.92% | 213,810 | +48% | 0.03% | $1,190,922 |
| Brevan Howard Capital Management LP | 0.91% | 212,367 | 0.01% | $1,182,884 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.88% | 206,133 | +9.8% | 0% | $1,148,848 |
| UBS Group AG | 0.83% | 194,017 | +119% | 0% | $1,080,675 |
| GROUP ONE TRADING LLC | 0.82% | 191,527 | +87% | 0.04% | $1,066,805 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
6
Latest
Q1 2026
Rows shown
1-6 of 6
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 10,378 | $101,394 | +$101,364 | $9.88 | 2 |
| 2026 Q1 | 17,581,515 | $97,927,900 | +$39,559,074 | $5.57 | 76 |
| 2025 Q4 | 9,456,135 | $69,598,197 | +$47,945,529 | $7.36 | 68 |
| 2025 Q3 | 2,947,949 | $19,279,960 | -$7,678,877 | $6.54 | 51 |
| 2025 Q2 | 4,384,748 | $18,898,424 | +$4,718,131 | $4.31 | 49 |
| 2025 Q1 | 3,312,099 | $12,386,156 | +$12,277,831 | $3.74 | 47 |